Mitchell Lawrence Jones - 04 Sep 2025 Form 4 Insider Report for PALISADE BIO, INC. (PALI)

Reporting relationship: Chief Medical Officer
Issuer ticker: PALI
Reported as of: 04 Sep 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Sep 2025, 09:00:35 UTC
Prior SEC filing: 13 Feb 2025
Next SEC filing: 08 Oct 2025
Source filing: View source filing
Reporting owner signature: /s/ Ryker Willie, Attorney-in-Fact

Key filing fact

Mitchell Lawrence Jones filed Form 4 for PALISADE BIO, INC. (PALI) on 05 Sep 2025.

Key facts

This page summarizes Mitchell Lawrence Jones's Form 4 filing for PALISADE BIO, INC. (PALI).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 05 Sep 2025, 09:00.

Change

Previous filing in this sequence was filed on 13 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001993292 Primary reporting owner

Jones Mitchell Lawrence

Relationship: Chief Medical Officer
Address: 1902 WRIGHT PLACE, SUITE 200, CARLSBAD,
Signature: /s/ Ryker Willie, Attorney-in-Fact
Signature date: 05 Sep 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PALI transaction Derivative

Phantom Units

Award

Transaction value: $0
Shares: +289,000
Change %
Price: $0.000000
Shares after: 289,000
Date: 04 Sep 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 289,000
Exercise price
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each Phantom Unit is the economic equivalent of one share of the Issuer's common stock.

Footnote F2

The Phantom Units vest in 12 equal quarterly installments beginning on November 5, 2025, subject to the Reporting Person's continuous service through each applicable vesting date.

Footnote F3

Vested Phantom Units shall be settled solely in cash based on the fair market value of an equal number of shares of the Issuer's common stock on the earliest to occur of any of the following events: (a) termination of the Reporting Person's continuous service by the Issuer without Cause; (b) a Liquidity Change in Control of the Issuer; or (c) 7th anniversary of the grant date, in each case as such capitalized terms are defined in the Issuer's Phantom Unit Plan.

SEC remarks

Exhibit 24 - Power of Attorney